Paratek begins dosing in Phase III trial of omadacycline to treat ABSSSI
The trial is designed to evaluate the efficacy and safety of omadacycline compared with linezolid in ABSSSI. Omadacycline is the first in a new class of tetracyclines called
XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule therapeutics targeting a G protein-coupled receptor (GPCR).
The application covers InVivo’s investigational Neuro-Spinal Scaffold, which is currently being studied in a pilot clinical trial and has been successfully implanted in three patients. Also covered is